COMMUNIQUÉS West-GlobeNewswire

Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
29/10/2025
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing Phase 3 gMG trial planned [...]
Veru Announces Proposed Public Offering
29/10/2025
MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory [...]
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
29/10/2025
TX45 improved both left heart function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (“PH‑HFrEF”) TX45 was well tolerated in patients with PH‑ [...]
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
29/10/2025
- $120.7 million in total third quarter revenue, comprised of $108.1 million of U.S. Attruby® net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue - As of October 25, [...]
MIMEDX Announces Record Revenue for Third Quarter 2025
29/10/2025
Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million [...]
Spyre Therapeutics to Participate in Upcoming November Investor Conferences
29/10/2025
WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
Teladoc Health Reports Third Quarter 2025 Results
29/10/2025
NEW YORK, NY, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended September 30, 2025 (“Third Quarter 2025 [...]
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
29/10/2025
Company’s first metered-dose inhalation (MDI) product and establishes a new growth vector for the Affordable Medicines segment BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” [...]
Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team
29/10/2025
Renowned pain management and medical technology leader to accelerate Glucotrack’s strategy for integrated glucose monitoring applications, building on Company’s 2024 expansion into epidural monitoring RUTHERFORD, N.J., [...]
Seer to Participate in Upcoming November Investor Conferences
29/10/2025
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the [...]
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025
29/10/2025
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
29/10/2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2025 financial results will be released before the market opens [...]
Prenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth
29/10/2025
Comprehensive Document Reveals Strategic Vision Behind Company's Unprecedented Growth and Bitcoin Treasury Strategy IM8, the Fastest-Growing Supplement Brand in Industry History, Reaching Reaches $100M ARR in 11 Months [...]
OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results
29/10/2025
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months [...]
AVITA Medical to Announce Third Quarter 2025 Financial Results
29/10/2025
VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, [...]
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
29/10/2025
Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 million Third Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22% Third Quarter 2025 Gross Margin % of 54 [...]
Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day
29/10/2025
Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is generally safe and [...]
STERIS Announces Dividend of $0.63 per share
29/10/2025
DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on [...]
Cytek® Biosciences Deepens Commitment to Expanding Access to Flow Cytometry
29/10/2025
Supports ISAC in Mission to Extend Flow Cytometry Reach Worldwide; Unveils Programs Offering Instrument Award and Research Grants FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various [...]

Pages